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A wide variety of novel therapeutic strategies were pre-
sented at the 12th International Conference on Alzheimer’s 
Drug discovery hosted by the Alzheimer’s Drug Discovery 
Foundation (ADDF). Th   is report highlights novel strate-
gies funded by the ADDF that are progressing through 
the drug development pipeline (Figure 1).
Neuroprotective strategies
Th  erapies that are neuroprotective or neurotrophic and 
can protect against neuronal loss are attractive targets in 
preventing or slowing the progression of Alzheimer’s 
disease (AD). Carmela Abraham (Boston University 
School of Medicine, USA) discussed the development of 
modulators of Klotho expression, a protein that has been 
shown to decrease with age and regulate maturation of 
myelinating oligodendrocytes. Th  ree hit compounds 
were identiﬁ  ed from a high-throughput screen (HTS) of 
150,000 compounds that inhibit methylation at CpG 
islands and thereby increase Klotho expression. Hits have 
been validated in several cell lines and are now under-
going a medicinal chemistry strategy to ensure a desirable 
pharmacological proﬁ   le. A second neuroprotective 
strategy was highlighted by Eugenia Trushina (Mayo 
Clinic College of Medicine, USA). Trushina and team 
identiﬁ  ed and characterized an orally available and blood 
brain barrier (BBB) permeable tricyclic pyrone, CP-2, 
which eliminates 80% of amyloid deposits (ﬁ  brillar and 
oligomers) in the 5x familial AD (FAD) transgenic model. 
Probing the mechanism of action revealed metabolomic 
changes and altered mitochondrial traﬃ   cking and func-
tion prior to the onset of memory and neurological pheno-
types, all of which were reversible with CP-2 treatment.
Other novel neuroprotective strategies targeted neuro-
inﬂ  ammation through the orally available tetramethyl-
pyrazine (TMP), derived from a Chinese medical herb 
(Ziqun Tan, University of California, USA). Martin 
Watterson (Northwestern University, USA) presented the 
develop  ment program for MW151, a small molecule 
modulator of p38α mitogen-activated protein kinase 
(MAPK) activity in neuronal and glial cells with 
‘druggability’ at the forefront of development. Watterson 
and colleagues undertook a strategic medicinal chemistry 
program to address the major barriers to AD thera-
peutics: central nervous system penetrance and undesired 
pharmacology. Th   is program resulted in the development 
of MW151, a highly selective, BBB penetrable compound 
that eﬀ   ectively attenuated pro-inﬂ  ammatory  cytokine 
production and reversed behavioral deﬁ  cits  following 
oral administration in an amyloid-β-induced brain injury 
mouse model.
Robert Mahley (University of California, USA) presen-
ted an update on PY101, a small molecule that restores 
apolipoprotein E4 (ApoE4) to an ApoE3-like structure. 
Ten-day oral adminis  tration of PY101 in the neuron-
speciﬁ   c enolase ApoE4 (NSE-ApoE4) mouse model 
resulted in decreased production of toxic ApoE frag-
ments and increased mito  chon  drial cyclooxygenase-1 
levels in the hippo  cam  pus. Identi  ﬁ   cation of this toxic 
gain of function for ApoE4 opens up additional targets in 
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neuron-speciﬁ  c proteolysis of ApoE4 and mitochondrial 
protectors to prevent ApoE4 fragment interaction with 
mitochondria. Finally, the most advanced of these 
neuroprotective strategies, in phase II/III for the orphan 
neuro  degener  ative disease progressive supranuclear 
palsy (PSP), was presented by Illana Gozes (Allon Th  era-
peutics, USA). Allon Th  era  peutics’ drug (davunetide), a 
short eight amino acid frag  ment of activity dependent 
neurotrophic factor (ADNF), met limited eﬃ   cacy end-
points in a phase II AD trial, but is now being tested in an 
improved formulation for PSP.
Calcium homeostasis and plasticity
Histone deacetylase (HDAC)2 has been previously impli-
cated in memory formation and synaptic plasticity; 
however, the development of HDAC2-speciﬁ  c inhibitors 
has been challenging. To reduce the toxicity associated 
with this class of compounds, Pavel Petukhov (University 
of Illinois, USA) screened compounds using Binding 
Ensemble Proﬁ  ling with Photoaﬃ   nity Labeling to speci-
ﬁ  cally identify compounds that bind in an orientation 
that prevents chelation of the zinc group. Th  is screen 
identiﬁ  ed a lead compound with an improved pharmaco-
kinetic and toxicity proﬁ  le.
Altered calcium homeostasis, speciﬁ  cally  increased 
endoplasmic reticulum calcium release, has been linked 
to a number of sporadic AD risk factors and is thought to 
underlie altered synaptic transmission and plasticity. 
Grace Stutzmann (Rosalind Franklin University School of 
Medicine, USA) and colleagues were the ﬁ  rst to observe 
that the endoplasmic reticulum-resident ryanodine 
recep  tor (RyR) diﬀ  erentially regulates synaptic transmis-
sion and plasticity in non-transgenic and AD transgenic 
mice. Chronic treatment of 3x FAD transgenic mice with 
the RyR antagonist dantrolene (injection) normalized 
calcium signaling by preventing increased endoplasmic 
reticulum RyR-mediated calcium release, validating RyR 
as a potential target for further screening.
Increased intracellular calcium levels aﬀ  ect numerous 
cellular functional processes via calcium-sensitive proteins. 
Visinin-like protein 1 (VILIP1), a neuronal calcium 
sensor protein discovered by Karl-Heinz Braunewell 
(Southern Research Institute, USA) regulates the cell 
surface localization of α4β2 nicotinic acetylcholine recep-
tors. VILIP1 receptors are decreased in the hippocampus, 
amygdala and cortical areas of AD patients. A phenotypic 
and biochemical HTS of 2,000 compounds identiﬁ  ed 2 
lead compounds that will now be optimized for the 
desired pharmacological properties.
Protein folding and degradation
Heat shock proteins (HSPs) promote the correct folding 
and refolding of misfolded proteins, including tau, 
amyloid-β, and α-synuclein, and are therefore attractive 
targets for a number of neurodegenerative diseases. 
Several approaches to target HSP70 and HSP90 were 
presented. Allen Reitz (ALS Biopharma, USA) identiﬁ  ed 
hit com  pounds that lowered tau levels by inducing 
HSP70 expression in human glioblastoma cell lines. 
Under  standing the mechanism of action of a target is 
vitally important during drug design. Th  is point was 
highlighted by Chad Dickey (University of South Florida, 
USA), who discovered that inhibition of HSP70 ATPase 
activity could also be eﬀ  ective at stabilizing disorganized 
tau. Inhibitors from a HTS based on rhodacyanine dyes 
have now been validated for their ability to decrease tau 
accumulation and rescue long-term potentiation in 
hippocampal slice cultures from Tg4510 tau mice. A 
second member of the heat shock family, HSP90, was the 
focus of Gabriela Chiosis’s (Memorial Sloan Kettering 
Cancer Center, USA) drug discovery program. Chiosis 
identiﬁ   ed two populations of HSP90 in pathogenic or 
stressed tissue (tumors and dystrophic neurons); a good 
housekeeping HSP90 complex and an HSP90 complex 
that selectively binds to pathogenic protein. Hsp90 
inhibitors developed by this team speciﬁ  cally bind the 
pathogenic HSP90 complex and reduce total tau and 
phospho-tau following acute treatment in the 3x FAD 
transgenic mouse model. Chronic studies will be required 
to assess behavioral outcomes.
Dysfunctional protein degradation pathways contribute 
to neurodegeneration. Karen Duﬀ   (Columbia University, 
USA) provided target validation for autophagy and 
proteasome targets demonstrating that mice with pro-
gres  sive tauopathy show a decline in proteasome function 
concomitant with an induction of autophagy and accu-
mulation of ﬁ  brillar tau aggregates. In vivo induction of 
autophagy following acute oral administration of trehalose, 
a non-reducing dissacharide, eﬀ   ectively decreased tau 
pathology in the P301L tau mouse model. Duﬀ   noted that 
the decreased proteosomal function seen during the 
onset of pathology could be reversed pharmacologically, 
highlighting both autophagy and proteasome activation 
as two potential drug targets in stimulating clearance of 
protein aggregates that present in numerous neuro-
degenerative diseases.
Lysosomal function plays a critical role in protein 
clearance. Lysosomal storage diseases, such as Gaucher 
disease, Fabry disease and Sandhoﬀ   disease, show evidence 
of accumulated intraneuronal amyloid-β in addition to 
decreased lysosome enzyme function. Brandon Wustman 
(Amicus Th   erapeutics, USA) and team have developed a 
set of novel pharmacological chaperones that enhance 
the activity of critical lysosomal enzymes, are orally 
available, cross the BBB, and are currently in phase III for 
Fabry disease. Now, Wustman and team are testing a 
novel, potent pharmacological chaperone for its eﬀ  ects in 
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cerebral amyloid angiopathy, an orphan indication with 
relevance to AD.
Additional strategies at the proof-of-concept stage 
targeted protein aggregates through immunotherapy. 
Rakez Kayed (University of Texas, USA) has developed 
an oligomer immunotherapy agent, TOMA (tau oligomer 
monoclonal antibody), that eﬀ   ectively reduced tau 
pathology following intracerebroventricular injection in 
the P301L tau mouse model. In the plenary session, Ryan 
Watts (Genentech, USA) demonstrated that β-site APP 
cleaving enzyme (BACE) monoclonal antibodies engineered 
to cross the BBB via the transferrin receptor eﬀ  ectively 
reduced BACE activity and amyloid-β levels without 
aﬀ  ecting total BACE expression in an AD mouse model.
Novel biomarkers
Th   e development of novel biomarkers to accurately diag-
nose AD prior to clinical manifestation and to predict 
conversion from mild cognitive impairment to AD is 
essential for the development of new therapeutics and 
understanding mechanisms of disease progression. 
Currently, the only deﬁ  nitive diagnostic tool for AD is at 
autopsy. Th  e most developmentally advanced imaging 
Figure 1. Development timeline of Alzheimer’s Drug Discovery Foundation-funded therapeutic strategies for Alzheimer’s disease and 
related dementias. Each program presented at the 12th International conference on Alzheimer’s Drug Discovery is highlighted in terms of 
position in the drug development lifecycle at the time of the meeting. *Allon Theraputics is currently in phase II/III for progressive supranuclear 
palsy, following limited effi   cacy in a phase II trial of davunetide for Alzheimer’s disease. NB: the purpose of this fi  gure is to highlight the stage of 
development for each program that has benefi  ted from Alzheimer’s Drug Discovery Foundation funding, and is not indicative of Alzheimer’s 
Drug Discovery Foundation funding throughout the entire program lifecycle. Multiple funders have contributed to many of these programs. Aβ, 
amyloid-β; ADME, absorption, distribution, metabolism and excretion; ADNF, activity dependent neurotrophic factor; AMPK, AMP activated protein 
kinase; APOE, apolipoprotein E; BACE, β-site APP cleaving enzyme; FTLD, frontotemporal lobar degeneration; HDAC, histone deacetylase; HSP, heat 
shock protein; mAb, monoclonal antibody; MAPK, mitogen-activated protein kinase; MSKCC, Memorial Sloan Kettering Cancer Center; PDI, protein 
disulphide isomerase; PoC, proof of concept; RyR, ryanodine receptor; TfR, transferrin receptor; TMP, tetramethylpyrazine; TOMA, tau oligomer 
monoclonal antibody; TOX, toxicity; VILIP, Visinin-like protein.
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by the US Food and Drug Administration (FDA). Daniel 
Skov  ronsky (Avid Radiopharmaceuticals, Inc., USA), 
funded by the Alzheimer’s Drug Discovery Foundation 
(ADDF) for the initial stages of development of 
ﬂ   orbetapir-positron emission tomography (PET), 
provided the opening plenary address. Florbetapir 18F is a 
PET imaging agent with high speciﬁ   city for amyoid-β 
binding. Skovronksy presented data from longitudinal 
analysis of normal older people with positive ﬂ  orbetapir-
PET scans and identiﬁ   ed a correlation between scan 
positivity and cognitive decline in normal older people, 
providing further evidence that amyloid-β load correlates 
with cognitive function.
Diagnostic tests that correctly diagnose diﬀ  erent causes 
of dementia are clinically challenging and remain a 
critical unmet need. Biomarkers that eﬃ   ciently distin  guish 
between frontotemporal lobar degeneration (FTLD) with 
TDP43 (TAR DNA-binding protein 43) or tau pathology 
are necessary for the development of disease-modifying 
treatments and to identify patients for inclusion/
exclusion from clinical trials. William Hu (Emory 
University School of Medicine, USA) provided an update 
on the program to identify relevant biomarker(s) using a 
targeted proteomics approach. Hu and colleagues 
identiﬁ   ed a panel of analytes from cerebrospinal ﬂ  uid 
samples that potentially distinguish between FTLD with 
TDP43 pathology and FTLD with tau pathology. Th  e 
team is currently recruiting patients for a multi-center 
study to validate this panel. Jeﬀ    Kuret (Ohio State 
University, USA) presented data on a HTS to identify 
selective radiolabeled compounds with high selectivity 
for tau by utilizing amino acid side chains of cross-β-
sheet aggre  gates to increase binding selectivity. Th  e  team 
has identiﬁ   ed potent lead candidates currently under 
optimization.
Allen Roses (Duke University, USA) highlighted the 
utility of biomarkers to enrich patient populations in 
clinical trials. Roses and team have identiﬁ  ed a region on 
chromosome 19 next to APOE that encodes the mito-
chondrial protein TOMM40 (translocase of outer mito-
chon  drial membrane 40 homolog) and can help explain 
the age-of-onset variability within the APOE genotype. 
Th  rough an algorithm-based approach, Roses and team 
are testing the prognostic value of the TOMM40 
genotype, APOE variants and age for patient inclusion in 
a trial of pioglitazone in normal subjects. To close the 
program, José Luchsinger (Columbia University, USA) 
presented the use of [18]F-labeled 2-deoxy-2-ﬂ  uoro-D-
glucose (FDG) PET with magnetic resonance imaging as 
a secondary endpoint for an ongoing phase II clinical 
trial for the anti-diabetic metformin in patients with mild 
cognitive impairment.
Th  e ADDF drug discovery portfolio encompasses a 
wide spectrum of novel targets in the generation of 
therapeutics for the treatment of AD and related 
dementias. Th   e work presented highlights the innovative 
approaches required during preclinical and clinical 
development. Th   e ADDF will continue to support novel 
targets in order to achieve our mission to conquer AD 
through drug discovery. Please join us for our 13th 
annual International Conference on Alzheimer’s Drug 
Discovery in the Fall of 2012 in Jersey City, NJ, USA.
Abbreviations
AD, Alzheimer’s disease; ADDF, Alzheimer’s Drug Discovery Foundation; APOE, 
apolipoprotein E; BACE, β-site APP cleaving enzyme; BBB, blood brain barrier; 
FAD, familial Alzheimer’s disease; FTLD, frontotemporal lobar degeneration; 
HDAC, histone deacetylase; HSP, heat shock protein; HTS, high-throughput 
screen; PET, positron emission tomography; PSP, progressive supranuclear 
palsy; RyR, ryanodine receptor; TDP43, TAR DNA-binding protein 43; TOMM40, 
translocase of outer mitochondrial membrane 40 homolog.
Competing interests
The authors declare that they have no competing interests.
Acknowledgements
This conference would not have been possible without the generous support 
of our sponsors: Pfi  zer Inc., Eli Lilly and Company, Elan Pharmaceuticals, Merck 
Research Laboratories, Allon Therapeutics, NeuroPhage Pharmaceuticals, JSW 
Life Sciences, Abbott Laboratories and Genentech.
Published: 20 December 2011
doi:10.1186/alzrt99
Cite this article as: Lane RF, et al.: Beyond amyloid: a diverse portfolio 
of novel drug discovery programs for Alzheimer’s disease and related 
dementias. Alzheimer’s Research & Therapy 2011, 3:36.
Lane et al. Alzheimer’s Research & Therapy 2011, 3:36 
http://alzres.com/content/3/6/36
Page 4 of 4